152 related articles for article (PubMed ID: 6429046)
41. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.
Pennington JE; Hickey WF; Blackwood LL; Arnaut MA
J Clin Invest; 1981 Nov; 68(5):1140-8. PubMed ID: 6795229
[TBL] [Abstract][Full Text] [Related]
42. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa. II. Isotype and functional activity of the anti-idiotype-induced antibodies.
Schreiber JR; Nixon KL; Tosi MF; Pier GB; Patawaran MB
J Immunol; 1991 Jan; 146(1):188-93. PubMed ID: 1898598
[TBL] [Abstract][Full Text] [Related]
43. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
44. Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides.
Cryz SJ; Meadow PM; Fürer E; Germanier R
Eur J Clin Microbiol; 1985 Apr; 4(2):180-5. PubMed ID: 3924605
[TBL] [Abstract][Full Text] [Related]
45. Immunological studies of an artificial antigen with specificity of a common polysaccharide antigen of Pseudomonas aeruginosa.
Makarenko TA; Kocharova NA; Edvabnaya LS; Tsvetkov YE; Kholodkova EV; Knirel YA; Backinowsky LV; Kochetkov NK; Stanislavsky ES
FEMS Immunol Med Microbiol; 1993 Oct; 7(3):251-6. PubMed ID: 7506094
[TBL] [Abstract][Full Text] [Related]
46. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.
Gilleland HE; Gilleland LB; Matthews-Greer JM
Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440
[TBL] [Abstract][Full Text] [Related]
47. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
[TBL] [Abstract][Full Text] [Related]
48. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Fürer E
Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
[TBL] [Abstract][Full Text] [Related]
49. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
50. Protective activities of ribosomal ribonucleic acid and lipopolysaccharide of Pseudomonas aeruginosa: a comparative study.
Gonggrijp R; Mullers WJ; van Boven CP
Antonie Van Leeuwenhoek; 1983 Jun; 49(2):173-82. PubMed ID: 6193755
[TBL] [Abstract][Full Text] [Related]
51. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
Moody MR; Kessel RW; Young VM; Fiset P
Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
[TBL] [Abstract][Full Text] [Related]
52. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice.
Rioux S; Dubreuil D; Bégin C; Laferrière C; Martin D; Jacques M
Comp Immunol Microbiol Infect Dis; 1997 Jan; 20(1):63-74. PubMed ID: 9023043
[TBL] [Abstract][Full Text] [Related]
54. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
Pennington JE; Pier GB; Sadoff JC; Small GJ
Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
[TBL] [Abstract][Full Text] [Related]
55. [The protective activity of 2 normal immunoglobulin preparations for intravenous administration in experimental Pseudomonas aeruginosa infection].
Vasilev ChL; Veleva KV; Tekelieva RKh; Pencheva PI
Zh Mikrobiol Epidemiol Immunobiol; 1991 Feb; (2):54-6. PubMed ID: 1907793
[TBL] [Abstract][Full Text] [Related]
56. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
Markham RB; Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
[TBL] [Abstract][Full Text] [Related]
57. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae.
Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S
Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454
[TBL] [Abstract][Full Text] [Related]
58. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A
Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466
[TBL] [Abstract][Full Text] [Related]
59. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.
Johansen HK; Espersen F; Cryz SJ; Hougen HP; Fomsgaard A; Rygaard J; Høiby N
Infect Immun; 1994 Aug; 62(8):3146-55. PubMed ID: 8039883
[TBL] [Abstract][Full Text] [Related]
60. Immunological study of antisera to to artificial O-antigen of Pseudomonas aeruginosa.
Edvabnaya LS; Stanislavskii ES; Lany B; Schiller B; Bichowicz I
J Hyg Epidemiol Microbiol Immunol; 1981; 25(2):163-8. PubMed ID: 6166668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
